Coloplast (CPSE:COLO B) - Hisse Senedi Fiyatı, Haberler ve Analizler

COLO B Stoklara Genel Bakış

Coloplast A/S, Danimarka, Amerika Birleşik Devletleri, Birleşik Krallık, Fransa'da ve uluslararası alanda samimi sağlık ürünleri ve hizmetlerinin geliştirilmesi ve satışı ile ilgilenmektedir. Daha fazla detay

COLO B temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	3/6
Finansal Sağlık	2/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 41% daha düşük bir oranda işlem görüyor

Kazançların yılda 12.85% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 4.9% oranında arttı

Risk Analizi

Borç işletme nakit akışı tarafından iyi karşılanmıyor

2.47% temettüsü kazançlar veya serbest nakit akışları tarafından iyi karşılanmıyor

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Key Takeaways Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term. Strategic acquisitions and growth in niche markets are projected to boost revenue and transform key business segments.

View narrative

DKK 911.19

2.3% undervalued

8.48%

Revenue growth p.a.

11 days ago

Coloplast A/S Rakipler

Demant

CPSE:DEMANT

DKK 57.7b

Ambu

CPSE:AMBU B

DKK 30.5b

Embla Medical hf

CPSE:EMBLA

DKK 15.3b

Cooper Companies

NasdaqGS:COO

US$19.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Coloplast
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 890.00
52 Haftanın En Yüksek Seviyesi	DKK 977.60
52 Haftanın En Düşük Seviyesi	DKK 739.60
Beta	0.34
11 Aylık Değişim	-0.71%
3 Aylık Değişim	0.25%
1 Yıllık Değişim	18.32%
33 Yıllık Değişim	-24.67%
5 Yıllık Değişim	11.33%
Halka arzdan bu yana değişim	6,865.22%

Son Haberler & Güncellemeler

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Hissedar Getirileri

	COLO B	DK Medical Equipment	DK Pazar
7D	-4.2%	-1.2%	-3.1%
1Y	18.3%	16.5%	5.7%

Getiri vs. Endüstri: COLO B geçen yıl % 16.5 oranında getiri sağlayan Danish Medical Equipment sektörünü aştı.

Getiri vs Piyasa: COLO B geçen yıl % 5.7 oranında getiri sağlayan Danish Piyasasını aştı.

Fiyat Oynaklığı

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.7%
Medical Equipment Industry Average Movement	3.7%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: COLO B son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: COLO B 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1954	16,639	Kristian Villumsen	www.coloplast.com

Coloplast A/S, Danimarka, Amerika Birleşik Devletleri, Birleşik Krallık, Fransa ve uluslararası alanda samimi sağlık ürünleri ve hizmetlerinin geliştirilmesi ve satışı ile ilgilenmektedir. Şirket, Kronik Bakım, Kontinans Bakımı, Ses ve Solunum Bakımı, Girişimsel Üroloji ve Gelişmiş Yara Bakımı segmentleri aracılığıyla faaliyet göstermektedir. Çeşitli ostomi türleri için bireysel vücut şekillerine uyum ve optimum takdir sağlayan SenSura Mio ve SenSura Ostomi bakım çözümlerinin yanı sıra Brava markası altında ostomi aksesuarları da dahil olmak üzere ostomi bakım ürünleri sunmaktadır.

Coloplast A/S Temel Bilgiler Özeti

Coloplast'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
COLO B temel i̇stati̇sti̇kler
Piyasa değeri	DKK 202.89b
Kazançlar(TTM)	DKK 5.05b
Gelir(TTM)	DKK 27.03b

39.7x

F/K Oranı

7.4x

P/S Oranı

COLO B aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
COLO B gelir tablosu (TTM)
Gelir	DKK 27.03b
Gelir Maliyeti	DKK 8.76b
Brüt Kâr	DKK 18.27b
Diğer Giderler	DKK 13.22b
Kazançlar	DKK 5.05b

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Feb 04, 2025

Hisse başına kazanç (EPS)	22.44
Brüt Marj	67.59%
Net Kâr Marjı	18.69%
Borç/Özkaynak Oranı	120.6%

COLO B uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.5%

Mevcut Temettü Verimi

98%

Ödeme Oranı

COLO B güvenilir bir temettü ödüyor mu?

COLO B temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman COLO B satın almanız gerekir?
Coloplast temettü tari̇hleri̇
Eski Temettü Tarihi	Dec 06 2024
Temettü Ödeme Tarihi	Dec 10 2024
Eski temettüye kadar geçen günler	17 days
Temettü ödeme tarihine kadar geçen günler	21 days

COLO B güvenilir bir temettü ödüyor mu?

COLO B temettü geçmişine ve kıyaslamalara bakın

COLO B Stoklara Genel Bakış

Ödüller

Risk Analizi

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Coloplast A/S Rakipler

CPSE:DEMANT

DKK 57.7b

CPSE:AMBU B

DKK 30.5b

CPSE:EMBLA

DKK 15.3b

NasdaqGS:COO

US$19.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being